advertisement
11.14 Investigational drugs; pharmacological experiments (136)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Cao T
Neuroimmunomodulation 2021; 0: 1-10
92580 Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma
Amankwa CE
Antioxidants (Basel, Switzerland) 2021; 10:
92669 Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control
van der Merwe Y
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; 0:
92055 Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
Al-Humimat G
Journal of experimental pharmacology 2021; 13: 197-212
92762 Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents
Prager AJ
Ophthalmology. Glaucoma 2021; 4: 597-603
92303 The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
Rozpędek-Kamińska W
International journal of molecular sciences 2021; 22:
92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Zaman F
Current Medical Research and Opinion 2021; 37: 1011-1020
92476 Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Roddy GW
Current Eye Research 2021; 0: 1-6
92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée A
Biomedicines 2021; 9:
92635 Rhopressa-induced corneal edema: a case report
Chu MJ
Journal of Medical Case Reports 2021; 15: 182
92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Tan C
Journal of materials chemistry. B 2021; 9: 3335-3345
92335 Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy
Riva I
European Journal of Ophthalmology 2021; 0: 1120672121999344
92541 Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma
Mehta AA
European Journal of Ophthalmology 2021; 0: 1120672121998913
92680 Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis
Li G
eLife 2021; 10:
92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée A
Biomedicines 2021; 9:
92695 Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma
Baba T
Scientific reports 2021; 11: 5812
92168 New considerations for the clinical efficacy of old and new topical glaucoma medications
MacIver S
Clinical and Experimental Optometry 2021; 104: 350-366
92720 Netarsudil-related Eyelid Wound Dehiscence
Kim HM
Journal of Glaucoma 2021; 30: 206-208
92662 Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Batra M
European Journal of Ophthalmology 2021; 0: 11206721211008783
92458 MiR-137 promotes cell growth and inhibits extracellular matrix protein expression in HO-induced human trabecular meshwork cells by targeting Src
Wang L
Neuroscience Letters 2021; 755: 135902
92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Araie M
Advances in Therapy 2021; 38: 1757-1775
92784 The ROCK Inhibitor Ripasudil Shows an Endothelial Protective Effect in Patients With Low Corneal Endothelial Cell Density After Cataract Surgery
Fujimoto H
Translational vision science & technology 2021; 10: 18
92310 Antiglaucoma Potential of β-Glucogallin Is Mediated by Modulating Mitochondrial Responses in Experimentally Induced Glaucoma
Wang J
Neuroimmunomodulation 2021; 0: 1-10
92570 A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
Gieser SC
Current Medical Research and Opinion 2021; 37: 1011-1020
92360 Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée JN
Biomedicines 2021; 9: